MAY 03, 2018 8:00 AM PDT

Fecal Lactoferrin Measurements in Clinical Practice

Speaker
  • Assistant Professor of Pediatrics, Harvard Medical School and Program Director, HMS Fellowship in Pediatric Gastroenterology, Boston Children's Hospital
    BIOGRAPHY

Abstract

DATE:  May 3rd, 2018

TIME:   8:00 AM PDT, 11:00 AM EDT

Intestinal inflammation is a hallmark of the inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease.  These chronic autoimmune GI illnesses affect upwards of 3 million children and adults in the United States.  Many of the symptoms in patients with IBD overlap with those observed in patients with irritable bowel syndrome (IBS), a discrete and likely pathogenically pleomorphic gastrointestinal illness. Nonetheless, there is a premium on making a distinction between IBD and IBS as their treatment differs significantly.  Fecal lactoferrin testing is a non-invasive metric that can be used to help differentiate patients presenting with non-specific gastrointestinal symptoms as having either IBD or IBS.  Previous data have demonstrated that fecal lactoferrin levels may also useful in tracking disease activity or assessing response to therapy.  Several factors make lactoferrin a particularly useful biomarker:  it is structurally stable and not sensitive to bacterial proteases in the intestinal lumen, it has a steady baseline with well-defined clinical cutoffs, and has broad applicability as it is reliable in virtually any scenario in which a clinician is trying to discern if a particular patient is presenting with an infectious, autoimmune, or inflammatory gastrointestinal disease. These attributes can be leveraged to provide improve health outcomes while decreasing the economic burden on the healthcare system.

Learning Objectives:

  • Identify scenarios in which fecal lactoferrin testing may aid in diagnosis
  • Recognize when fecal lactoferrin levels may be useful in tracking disease activity or assessing response to therapy
  • Use fecal lactoferrin biomarkers as a first-step diagnostic strategy to minimize the need for scoping on certain patient populations, like pediatrics, for whom a more non-invasive diagnostic tool is beneficial

This webinar has been approved for Continuing Education credits.  Please see the following link for more information about the CME credits being provided; CME Credits


Show Resources
You May Also Like
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
FEB 24, 2022 10:00 AM PST
C.E. CREDITS
FEB 24, 2022 10:00 AM PST
Date: February 24, 2021 Time: 10:00am (PST), 1:00pm (EST) One of the largest global public health crises is the rise of antimicrobial-resistant infections. Globally, over 700,000 people die...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
MAY 03, 2018 8:00 AM PDT

Fecal Lactoferrin Measurements in Clinical Practice



Show Resources
Loading Comments...
Show Resources